| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-530SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 443-KD-050/CF | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB4431-SP | |||
| Carrier Free | MAB4431-500 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB3573-SP | |||
| Carrier Free | MAB3573-500 | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alexa Fluor 350 | FAB443U-100UG | |||
| Alexa Fluor 405 | FAB443V-100UG | |||
| Alexa Fluor 488 | FAB443G-100UG | |||
| Alexa Fluor 532 | FAB443X-100UG | |||
| Alexa Fluor 594 | FAB443T-100UG | |||
| Alexa Fluor 647 | FAB443R-100UG | |||
| Alexa Fluor 700 | FAB443N-100UG | |||
| Alexa Fluor 750 | FAB443S-100UG | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB443-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-529SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP3-05772SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP1-18646-0.02mg | |||
![Western Blot: VEGFR2/KDR/Flk-1 Antibody [NB100-530] - Detection of VEGF R2/KDR/Flk-1 doublet in CSF-1 receptor/VEGF R2/KDR/Flk-1 chimera transfected lysate (20 ug) using NB100-530 (0.5 ug/mL). ECL detection 10 seconds.](http://images.novusbio.com/fullsize/VEGFR2-KDR-Flk-1-Antibody-Western-Blot-NB100-530-img0009.jpg "Western Blot: VEGFR2/KDR/Flk-1 Antibody [NB100-530] - Detection of VEGF R2/KDR/Flk-1 doublet in CSF-1 receptor/VEGF R2/KDR/Flk-1 chimera transfected lysate (20 ug) using NB100-530 (0.5 ug/mL). ECL detection 10 seconds.")
![Immunocytochemistry/Immunofluorescence: VEGFR2/KDR/Flk-1 Antibody [NB100-530] - Immunohistochemical analyses of VEGFR2, Ang-2, vWF and CD34 in the peri-infarct area of the ischemic brain. Representative merged images counterstained with DAPI (nuclear staining) (blue). Ang-2, VEGFR2, vWF and CD34 antibodies are represented by the green color (arrows). Image collected and cropped by Citeab from the following publication (A Short Bout of Exercise Prior to Stroke Improves Functional Outcomes by Enhancing Angiogenesis. Neuromolecular Med (2019) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/VEGFR2-KDR-Flk-1-Antibody-Immunocytochemistry-Immunofluorescence-NB100-530-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: VEGFR2/KDR/Flk-1 Antibody [NB100-530] - V6.5 mouse embryonic stem cells (cat# NBP1-41162) stained with Dylight 488 (Green). Alpha-tubulin and nuclei were counterstained against Dylight 550 (Red) and DAPI (Blue).](http://images.novusbio.com/fullsize/VEGFR2-KDR-Flk-1-Antibody-Immunocytochemistry-Immunofluorescence-NB100-530-img0008.jpg)
![Western Blot: VEGFR2/KDR/Flk-1 Antibody [NB100-530] - Top: relative expression of CD36, GLUT2, & VEGFR2 in duodenum; n = 6–8. All values are expressed as model-based means, with error bars representing the confidence intervals (95% CI). *P value < 0.05. Bottom: Western blots of CD36 (75 kDa), GLUT2 (55 kDa), & VEGFR2 (105 kDa). Animals without a detectable band were excluded from the analysis. HIIT, high-intensity interval training; MICT, moderate-intensity continuous training; CON, control group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28183816), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-530_rabbit-polyclonal-vegfr2-kdr-flk-1-antibody-310202415334928.jpg)
![N/A VEGFR2/KDR/Flk-1 [Biotin]](http://images.novusbio.com/fullsize2/DATA_VEGF_R2_DY357_ELISA_1959.jpg "N/A VEGFR2/KDR/Flk-1 [Biotin]")
![ELISA VEGFR2/KDR/Flk-1 [Biotin]](http://images.novusbio.com/fullsize2/dyc1780-2_human-total-vegf-r2-kdr-duoset-ic-elisa-5-plate-elisa-16920209736.jpg "ELISA VEGFR2/KDR/Flk-1 [Biotin]")
![Western Blot: VEGF R2/KDR/Flk-1 Antibody [NB100-529] - Detection of VEGF R2/KDR/Flk-1 doublet in VEGFA induced HUVEC cell lysate (50 ug) using NB100-529 (4 ug/mL). ECL detection 2.5 minutes.](http://images.novusbio.com/fullsize/VEGF-R2-KDR-Flk-1-Antibody-Western-Blot-NB100-529-img0010.jpg "Western Blot: VEGF R2/KDR/Flk-1 Antibody [NB100-529] - Detection of VEGF R2/KDR/Flk-1 doublet in VEGFA induced HUVEC cell lysate (50 ug) using NB100-529 (4 ug/mL). ECL detection 2.5 minutes.")
![Immunocytochemistry/Immunofluorescence: VEGF R2/KDR/Flk-1 Antibody [NB100-529] - The VEGF R2/KDR/Flk-1antibody was tested in V6.5 mouse embryonic stem cells (NBP1-41162) with DyLight 488 (Green). Alpha-tubulin and nuclei were counterstained with DyLight 550 (Red) and DAPI (Blue), respectively.](http://images.novusbio.com/fullsize/VEGF-R2-KDR-Flk-1-Antibody-Immunocytochemistry-Immunofluorescence-NB100-529-img0008.jpg)
![Western Blot: VEGF R2/KDR/Flk-1 Antibody [NB100-529] - Detection of VEGF R2/KDR/Flk-1 doublet in CSF-1 receptor/VEGF Receptor 2 chimera transfected lysate (20 ug) using NB100-529 (6 ug/mL). ECL detection 30 seconds.](http://images.novusbio.com/fullsize/VEGF-R2-KDR-Flk-1-Antibody-Western-Blot-NB100-529-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: VEGFR2/KDR/Flk-1 Antibody [NBP3-05772] - HepG2 cells were fixed for 10 minutes using 4% PFA and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton-X100. The cells were incubated with anti-VEGFR2/KDR at 2 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/VEGFR2-KDR-Flk-1-Antibody-Immunocytochemistry-Immunofluorescence-NBP3-05772-img0002.jpg "Immunocytochemistry/Immunofluorescence: VEGFR2/KDR/Flk-1 Antibody [NBP3-05772] - HepG2 cells were fixed for 10 minutes using 4% PFA and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton-X100. The cells were incubated with anti-VEGFR2/KDR at 2 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.")
![Immunohistochemistry-Paraffin: VEGFR2/KDR/Flk-1 Antibody [NBP3-05772] - Analysis of a FFPE tissue section of mouse kidney using 1:200 dilution of VEGFR2 antibody. The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.](http://images.novusbio.com/fullsize/VEGFR2-KDR-Flk-1-Antibody-Immunohistochemistry-Paraffin-NBP3-05772-img0001.jpg)
![Western Blot: VEGFR2/KDR/Flk-1 Antibody (20I6) - Azide and BSA Free [NBP1-18646] - VEGFR2/KDR/Flk-1 Antibody (20I6) [NBP1-18646] - Recombinant human endogenous soluble VEGFR-2/KDR (esKDR) was produced in insect cells. Western blot was performed using our monoclonal anti-VEGFR-2 recognizing the soluble as well as the transmembrane form of KDR (left panal) and our new poyclonal antibody directed against the unique C-terminal end of the endogenous sKDR (CGRETILDHSAEAVGMP) recognizing solely the endogenous form but not sKDR (D7) and sKDR (D7)-Fc consisting of the full extraplasmatic domain. The endogenous sKDR generated by alternative splicing consists of the first 6 Ig-like loops with a unique c-terminal end.](http://images.novusbio.com/fullsize/VEGFR2-KDR-Flk-1-Antibody-20I6-Western-Blot-NBP1-18646-img0006.jpg "Western Blot: VEGFR2/KDR/Flk-1 Antibody (20I6) - Azide and BSA Free [NBP1-18646] - VEGFR2/KDR/Flk-1 Antibody (20I6) [NBP1-18646] - Recombinant human endogenous soluble VEGFR-2/KDR (esKDR) was produced in insect cells. Western blot was performed using our monoclonal anti-VEGFR-2 recognizing the soluble as well as the transmembrane form of KDR (left panal) and our new poyclonal antibody directed against the unique C-terminal end of the endogenous sKDR (CGRETILDHSAEAVGMP) recognizing solely the endogenous form but not sKDR (D7) and sKDR (D7)-Fc consisting of the full extraplasmatic domain. The endogenous sKDR generated by alternative splicing consists of the first 6 Ig-like loops with a unique c-terminal end.")
![Immunocytochemistry/Immunofluorescence: VEGFR2/KDR/Flk-1 Antibody (20I6) - Azide and BSA Free [NBP1-18646] - HMEC-1 CRL-3243 cells, stained with 1:50 VEGFR2/KDR/Flk-1 antibody (NBP1-18645AF488) (green) and DAPI (blue). Image from verified customer review.](http://images.novusbio.com/fullsize/VEGFR2-KDR-Flk-1-Antibody-20I6-Azide-and-BSA-Free-Immunocytochemistry-Immunofluorescence-NBP1-18646-img0016.jpg)
![Flow Cytometry: VEGFR2/KDR/Flk-1 Antibody (20I6) - Azide and BSA Free [NBP1-18646] - VEGFR2/KDR/Flk-1 Antibody (20I6) [NBP1-18646] - Analysis with primary human dermal lymphatic endothelial cells(HDLEC).](http://images.novusbio.com/fullsize/VEGFR2-KDR-Flk-1-Antibody-20I6-Flow-Cytometry-NBP1-18646-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: VEGFR2/KDR/Flk-1 Antibody (20I6) - Azide and BSA Free [NBP1-18646] - VEGFR2/KDR/Flk-1 Antibody (20I6) [NBP1-18646] - Staining (green) of VEGFR-2 (KDR) in primary human umbilical vein endothelial cells (HUVEC) with anti-human VEGFR-2 (Cl.4) (7,5ug/ml) and counter staining of nuclei with Dapi. As secondary antibody goat anti-mouse ALEXA Flour 488 (Dianova) was used 1:600.](http://images.novusbio.com/fullsize/VEGFR2-KDR-Flk-1-Antibody-20I6-Immunocytochemistry-Immunofluorescence-NBP1-18646-img0015.jpg)